Legend Biotech Corporation ADR (LEGN)
NASDAQ: LEGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LEGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.96B
- Forward P/E
- 28.89
- EPS (TTM)
- -$0.02
- Dividend yield
- None
- 52-week range
- 15.15 – 37.50
- Day range
- 15.15 – 16.11
- Volume / Avg
- 3.42M / 2.26M
- Beta
- —
- Shares outstanding
- 193.97M
52-week range
LEGN stock today
Legend Biotech (LEGN) closed at $15.25 on Nov 20, down 5.28% (-$0.85), versus the S&P 500's 3.70% decline. At this level, LEGN sits near the bottom of its 52-week range of $15.15 to $37.50: 59.3% below the high, set on Jun 3, 2026 and 0.7% above the low. LEGN is down 29.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.9%.
Legend Biotech has posted a net loss over the last twelve months (EPS of -$0.02), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Legend Biotech
Company profileLegend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Ingrid Zhang
- Headquarters
- Somerset, NJ
- Employees
- 3,300
- IPO year
- 2020
- Website
- legendbiotech.com
Financial highlights
Full financialsIn fiscal 2025, Legend Biotech generated $1.03 billion in revenue, up 64.0% from fiscal 2024, its 4th consecutive year of revenue growth. Legend Biotech reported a net loss of $296.8 million, compared with a loss of $177.0 million a year earlier. Gross margin was 61.4% (down from 65.5%) and operating margin -13.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.03B | $627.24M | $285.14M | $117.00M | $68.83M |
| Growth | +64.04% | +119.97% | +143.70% | +70.00% | -8.23% |
| Net income | $-296.80M | $-177.03M | $-518.25M | $-446.35M | $-403.58M |
| EPS (diluted) | $-0.81 | $-0.48 | $-1.47 | $-1.40 | $-1.43 |
Analyst forecast
ForecastConsensus (14 analysts)
buy
Avg. price target
$40.93+168.39%
- Strong buy 5
- Buy 3
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.11 vs $0.01
- Surprise
- -1200.00%
LEGN news
All LEGN news- Legend Biotech Reports Third Quarter 2026 Results and Recent HighlightsGlobeNewswire
- Legend Biotech Announces 7 Presentations at the 68th American Society of Hematology Annual MeetingNasdaqLEGN, HEI.A
- Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T TherapyGlobeNewswire
- After Hours Most Active for Sep 11, 2026 : KHC, ACWX, PATH, TSLL, GRAB, F, LEGN, AAPL, XPEV, KVUE, T, BMNRNasdaqKHC, ACWX, PATH, TSLL
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.NasdaqPTGX, JNJ, LAB, XNCR
- Pre-Market Earnings Report for August 11, 2026 : CAH, SE, ESLT, ARMK, ONON, SFD, VG, MIDD, AMTM, TME, LEGN, ETORNasdaqCAH, SE, ESLT, ARMK
Legend Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs LEGN |
| DYNDyne Therapeutics Inc. | 15.50 | -3.31% | $2.90B | vs LEGN |
| TLXTelix Pharmaceuticals Limited ADR | 8.37 | -3.90% | $2.84B | vs LEGN |
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs LEGN |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs LEGN |
| SLSSELLAS Life Sciences Group Inc. | 13.66 | -8.08% | $2.78B | vs LEGN |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs LEGN |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs LEGN |
Indexes, lists and sector
Legend Biotech stock FAQ
What is Legend Biotech's stock price today?
LEGN last traded at $15.25 as of Nov 20, 4:00 PM EST, down 5.28% on the day. Prices are delayed at least 15 minutes.
Who is Legend Biotech's CEO?
Ms. Ingrid Zhang is the chief executive officer of Legend Biotech Corporation ADR, which has about 3,300 employees.
What is the LEGN 52-week high?
The 52-week high for LEGN is $37.50 and the 52-week low is $15.15. The stock is currently 59.3% below its high.